Replies to post #125229 on Biotech Values

[BTH]

With Zelboraf as a melanoma treatment, assuming Vismodegib gets approval for inoperable BCC (also going in operable BCC in earlier stages), Roche will have a nice niche in the skin cancer segment.

[masterlongevity]

I think genentech and Novartis are still the top 2, with BMY 3rd and PFE 4th... at least in terms of innovation